Effectiveness of a personal health coaching intervention (diabetescoach) in patients with type 2 diabetes: protocol for an open-label, pragmatic randomised controlled trial

被引:3
|
作者
Hohberg, Vivien [1 ]
Kreppke, Jan-Niklas [1 ]
Kohl, Jan [2 ]
Seelig, Eleonora [3 ,4 ]
Zahner, Lukas [1 ]
Streckmann, Fiona [1 ,5 ]
Gerber, Markus [1 ]
Konig, Daniel [2 ,6 ]
Faude, Oliver [1 ]
机构
[1] Univ Basel, Dept Sport Exercise & Hlth, Basel, Switzerland
[2] Univ Freiburg, Inst Sports & Sport Sci, Freiburg, Germany
[3] Univ Hosp Basel, Endocrinol Diabetol & Metab, Basel, Switzerland
[4] Cantonal Hosp Basel Landschaft, Endocrinol & Diabetol, Vestal, Switzerland
[5] Univ Hosp Basel, Onkol, Basel, Switzerland
[6] Univ Vienna, Inst Nutr Exercise & Hlth, Vienna, Austria
来源
BMJ OPEN | 2022年 / 12卷 / 06期
关键词
LIPOPROTEIN INSULIN-RESISTANCE; LIFE-STYLE INTERVENTION; PHYSICAL-ACTIVITY; POSITION STATEMENT; METABOLIC SYNDROME; SELF-EFFICACY; OBESE ADULTS; EXERCISE; BEHAVIOR; RISK;
D O I
10.1136/bmjopen-2021-057948
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction The widespread prevalence of type 2 diabetes (T2D) not only influences patients' daily lives but also has an economic impact on society. Increasing physical activity and a healthy diet can delay the progression of T2D. Although there are evidence-based recommendations on diet and physical activity, patients with T2D have difficulties implementing them. An appropriate lifestyle intervention can address this problem. Methods and analysis This study is based on the need to develop an intervention that helps patients to establish behavioural changes in order to achieve glycaemic control. The intervention will be evaluated in a monocentric, open-label, pragmatic, two-arm randomised controlled trial with a sample ratio of 1:1 and a parallel design. This superiority study will be conducted in Switzerland. All enrolled patients (n=90) will receive the standard medical treatment for T2D. The intervention group will receive personal health coaching by telephone and access to a smartphone and web application for 1 year. The control group will receive access to the application for 1 year and a one-time written diet and exercise recommendation. The primary outcomes are objectively measured physical activity and glycated haemoglobin. Secondary outcomes are self-reported physical activity, nutrition, cognitive mediators of changes in sport-related behaviour, blood values, medication and nutritional supplements, anthropometric data, quality of life, neuropathy and cost-effectiveness. All outcomes will be measured at baseline, at 27 weeks after inclusion and at 54 weeks after inclusion. The recruitment of participants and the measurements will be completed after 2 years. Linear mixed-effects models will be applied for each outcome variable to analyse the intervention effects. Ethics and dissemination This study was approved by the Ethics Committee North-western and Central Switzerland in February 2021 (ref: 2020-02755). All participants will be required to provide written informed consent. The results will be published in international peer-reviewed journals.
引用
下载
收藏
页数:15
相关论文
共 50 条
  • [41] Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology
    Dwibedi, Chinmay
    Ekstroem, Ola
    Brandt, Jasmine
    Adiels, Martin
    Franzen, Stefan
    Abrahamsson, Birgitta
    Rosengren, Anders H.
    NATURE METABOLISM, 2024, 6 (01) : 50 - +
  • [42] Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology
    Chinmay Dwibedi
    Ola Ekström
    Jasmine Brandt
    Martin Adiels
    Stefan Franzén
    Birgitta Abrahamsson
    Anders H. Rosengren
    Nature Metabolism, 2024, 6 : 50 - 60
  • [43] Effectiveness of an integrated telehealth service for patients with depression: a pragmatic randomised controlled trial of a complex intervention
    Salisbury, Chris
    O'Cathain, Alicia
    Edwards, Louisa
    Thomas, Clare
    Gaunt, Daisy
    Hollinghurst, Sandra
    Nicholl, Jon
    Large, Shirley
    Yardley, Lucy
    Lewis, Glyn
    Foster, Alexis
    Garner, Katy
    Horspool, Kimberley
    Man, Mei-See
    Rogers, Anne
    Pope, Catherine
    Dixon, Padraig
    Montgomery, Alan A.
    LANCET PSYCHIATRY, 2016, 3 (06): : 515 - 525
  • [44] Yoga therapy on elderly patients with fear of fall: an open-label randomised controlled trial (YOFEAR trial)
    Kashyap, Kritartha
    Dhar, Minakshi
    Bisht, Khushboo
    Bahurupi, Yogesh
    Pathania, Monika
    BMJ OPEN, 2023, 13 (12):
  • [45] The effectiveness of a light-intensity physical activity intervention on cardiovascular health in people with type 2 diabetes: a randomised controlled trial
    Vandercappellen, E. J.
    Henry, R. M. A.
    Chen, Y.
    Niessen, P. M.
    Minten, M. J. M.
    Linkens, A. M. A.
    Simons, P. I. H.
    Jolani, S.
    Savelberg, H. H. C.
    Houben, A. J. H.
    Berendschot, T. T. J.
    Reesink, K. D.
    Muris, J. W. M.
    Stehouwer, C. D. A.
    Koster, A.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S430 - S430
  • [46] Medical assistant health coaching ("MAC") for type 2 diabetes in diverse primary care settings: A pragmatic, cluster-randomized controlled trial protocol
    Fortmann, Addie L.
    Philis-Tsimikas, Athena
    Euyoque, Johanna A.
    Clark, Taylor L.
    Vital, Daniela G.
    Sandoval, Haley
    Bravin, Julia, I
    Savin, Kimberly L.
    Jones, Jennifer A.
    Roesch, Scott
    Gilmer, Todd
    Bodenheimer, Thomas
    Schultz, James
    Gallo, Linda C.
    CONTEMPORARY CLINICAL TRIALS, 2021, 100
  • [47] Development of an information system and mobile application for the care of type 2 diabetes patients at the primary care level for the health sector in Mexico: study protocol for a randomized controlled, open-label trial
    Barengo, Noel C.
    Manuel Apolinar, Leticia
    Estrada Cruz, Norma A.
    Fernandez Garate, Jose E.
    Correa Gonzalez, Roberto A.
    Diaz Valencia, Paula A.
    Cinco Gonzalez, Cecilia Alicia
    Gomez Rodriguez, Jose Alberto
    Cisneros Gonzalez, Nelly
    TRIALS, 2022, 23 (01)
  • [48] Development of an information system and mobile application for the care of type 2 diabetes patients at the primary care level for the health sector in Mexico: study protocol for a randomized controlled, open-label trial
    Noël C. Barengo
    Leticia Manuel Apolinar
    Norma A. Estrada Cruz
    José E. Fernández Garate
    Roberto A. Correa González
    Paula A. Diaz Valencia
    Cecilia Alicia Cinco Gonzalez
    José Alberto Gómez Rodriguez
    Nelly Cisneros González
    Trials, 23
  • [49] Remission effect of Canagliflozin in patients with newly diagnosed type 2 diabetes mellitus: a protocol for a multicenter, parallel-group, randomized, controlled, open-label trial
    Yang, Xue
    He, Zhiwei
    Yuan, Li
    Huang, Wenbin
    Li, Doudou
    Xiang, Pingping
    Chen, Yu
    Chen, Guofang
    Liu, Chao
    BMC ENDOCRINE DISORDERS, 2023, 23 (01)
  • [50] Remission effect of Canagliflozin in patients with newly diagnosed type 2 diabetes mellitus: a protocol for a multicenter, parallel-group, randomized, controlled, open-label trial
    Xue Yang
    Zhiwei He
    Li Yuan
    Wenbin Huang
    Doudou Li
    Pingping Xiang
    Yu Chen
    Guofang Chen
    Chao Liu
    BMC Endocrine Disorders, 23